THE BASICS OF CHEMOEMBOLIZATION

Cover Page

Abstract


Chemoembolization has advantages over systemic chemotherapy as increase in drug concentration, time of exposition and decrease in systemic adverse effects.


D G Gitelson

Principal contact for editorial correspondence.
gitelson@rambler.ru
National Research Center for Hematology, Moscow, 125167, Russia Moscow, 125167, Russia

interventional radiologist of the National Research Center for Hematology

D A Rogov

konovalov_oe@rudn.university
National Research Center for Hematology, Moscow, 125167, Russia 126167, Москва, Россия

A E Vasiliev

konovalov_oe@rudn.university
National Research Center for Hematology, Moscow, 125167, Russia 126167, Москва, Россия

E A Gitelson

konovalov_oe@rudn.university
RUDN University, Moscow, 117198, Russia

  • Dolgushin B. I., Patutko Yu. I., Virshke E. R., Trofimov I. A., Cherkasov V. A., Kukushkin A. V., Kosirev V. Yu. & Sergeeva O. N. Arterialnaya himioembolizaciya mikrosferami, perenosyashimi dok-sorubicin, v lechenii bolnih gepatocellularnim rakom. Predvaritelnie resultati. Anali hirurgicheskoi gepatologii. 2009. Т. 14, N 2. С. 53—58.
  • Komov D. V., Roshin E. M., Kuchinskii G. A., Dolgushin B. I. & Virshke E. R. Itogi pervoi fazi klinicheskih issledovanii kompleksa doxorubicin-estron u bolnih so zlokachestvennimi novoobra-zovaniyami pecheni pri himiembolizacii c lipiodolom. Vestnik ONC AMN Rossii. 1997. N 4. С. 34—37.
  • Abdel-Rahman O. M. & Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepa-tocellular carcinoma. Cochrane Database Syst Rev. 2016. N 2. CD 011313.
  • Arciero C. A. & Sigurdson E.R. Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw. 2006. V. 4. N 8. P. 768—774.
  • Arciero C. A. & Sigurdson E. R. Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol. 2006. V. 7. N 5. P. 399—409.
  • Brown D.B. & Gould J. E. Practice building in interventional oncology. Tech Vasc Interv Radiol. 2006. V. 9. N 3. P. 90—95.
  • Gamma C., Schepis F., Orlando A. et al. Transarterial chemoembolization for unresectable hepato-cellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002. V. 224. P. 47—54.
  • Granov A. M., Tarazov P. G., Granov D. A., Polikarpov A. A. & Oleshchuk N. V. Successful treat-ment of patient with recurrent hepatocellular carcinoma. Vestn Khir Im I I Grek. 2015. V. 1. N 2. P. 98—100.
  • Guan Y. S., He Q. & Wang M. Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012. 480650.
  • Huang K., Zhou Q., Wang R., Cheng D. & Ma Y. Doxorubicin-eluting beads versus conventional tran-sarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014. V. 29. N 5. P. 920—925.
  • Kurup A. N. & Callstrom M. R. Ablation of musculoskeletal metastases: pain palliation, fracture risk reduction, and oligometastatic disease. Tech Vasc Interv Radiol. 2013. V. 16. N 4. P. 253—261.
  • Llovet J. M. & Bruix J. Systematic review of randomized trials for unresectable hepatocellular carci-noma: Chemoembolization improves survival. Hepatology. 2003. V. 37. P. 429—442.
  • Llovet J. M. & Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial emboliza-tion. Radiology. 2004. V. 2. N 1. P. 300—301.
  • Llovet J. M., Real M. I., Montaña X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Solà R., Rodés J. & Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoemboli-sation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a random-ised controlled trial. Lancet. 2002. V. 18. P. 1734—1739.
  • Lo C. M., Ngan H., Tso W. K. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002. V. 35. P. 1164—1171.
  • Malagari K., Chatzimichael K., Alexopoulou E. et al. Transarterial chemoembolization. World J Gastroenterol. 2015.V. 2. № 9. P. 420—424.
  • Miraglia R., Pietrosi G., Maruzzelli L., Petridis I., Caruso S., Marrone G., Mamone G., Vizzini G., Luca A. & Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol. 2007. V. 7. N 13. P. 2952—2955.
  • Park Y. N. & Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol. 2006. V. 45. N 5. P. 734—743.
  • Pereira P. L. & Masala S. Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: guidelines for thermal ablation of primary and secondary lung tu-mors. Cardiovasc Intervent Radiol. 2012. V. 35. N 2. P. 247—254.
  • Rammohan A., Sathyanesan J., Ramaswami S., Lakshmanan A., Senthil-Kumar P., Srini¬vasan U. P., Ramasamy R. & Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012. V. 28. № 4. P. 405—412.
  • The Royal College of Radiologists UK. Interventional Oncology: Guidance for Service delivery 2013—2016.
  • Tian X., Dai Y., Wang D. Q., Zhang L., Sui C. G., Meng F. D., Jiang S. Y., Liu Y. P. & Jiang Y. H. Tran-sarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther. 2015. V 10. N 9. P. 4431—4440.
  • Varela M., Real M. I., Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Hepatology. 2007. V. 46. N 3. P. 474—481.
  • Bruix J., Sala M. & Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004. V. 5. N 1. P. 179—188.
  • Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M. & Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with in-traarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989. V. 97. N 4. P. 965—971.
  • Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P. & Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unre¬sectable hepatocel-lular carcinoma. J Hepatol. 1990. V. 11. N 2. P. 181—184.
  • Kawai S., Okamura J., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma — a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 1—6.
  • Okamura J., Kawai S., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second coopera-tive study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 20—24.
  • Watanabe S., Nishioka M., Ohta Y., Ogawa N., Ito S. & Yamamoto Y. Prospective and random-ized controlled study of chemoembolization therapy in patients with advanced hepatocellular car-cinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol. 1994. V. 33. P. 93—96.

Views

Abstract - 19

PDF (Russian) - 31


Copyright (c) 2017 Gitelson D.G., Rogov D.A., Vasiliev A.E., Gitelson E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.